CrossRef Text and Data Mining

Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.

Crizotinib versus Chemotherapy in Asian Patients with ALK-Positive Advanced Non-small Cell Lung Cancer

Makoto Nishio, Dong-Wan Kim, Yi-Long Wu, Kazuhiko Nakagawa, Benjamin J. Solomon, Alice T. Shaw, Satoshi Hashigaki, Emiko Ohki, Tiziana Usari, Jolanda Paolini, Anna Polli, Keith D. Wilner, Tony Mok

Cancer Research and Treatment. 2018;50(3):691-700. Published online 2017 July 6 DOI: https://doi.org/10.4143/crt.2017.280

Spotlight on crizotinib in the first-line treatment of ALK-positive advanced non-small-cell lung cancer: patients selection and perspectives

Marie Wislez, Etienne Giroux-Leprieur, Vincent Fallet, Jacques Cadranel

Lung Cancer: Targets and Therapy. 2016;83

Link1

Cost effectiveness of ceritinib in patients previously treated with crizotinib and chemotherapy with anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer (NSCLC) in the United States

Yichen Zhang, Yixue Shao, Charles Stoecker, Lizheng Shi

. 2021;

Link1 Link2

Efficacy and Safety of Crizotinib among Chinese EML4-ALK-Positive, Advanced-Stage Non-Small Cell Lung Cancer Patients

Yabing Cao, Guangli Xiao, Xibin Qiu, Sheng Ye, Tongyu Lin

PLoS ONE. 2014;9(12):e114008

Link1

Crizotinib versus Chemotherapy in Asian Patients with ALK-Positive Advanced Non-small Cell Lung Cancer

Makoto Nishio, Dong-Wan Kim, Yi-Long Wu, Kazuhiko Nakagawa, Benjamin J. Solomon, Alice T. Shaw, Satoshi Hashigaki, Emiko Ohki, Tiziana Usari, Jolanda Paolini, Anna Polli, Keith D. Wilner, Tony Mok

Cancer Research and Treatment. 2018;50(3):691-700

Link1

Link2 Link3

Estimating the Budget Impact of Crizotinib for Alk-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) in Argentina

B. Wang, W. Furnback, J. Xuan

Value in Health. 2014;17(3):A74

Link1 Link2

Real-World Outcomes in Patients with Alk-Positive Non-Small Cell Lung Cancer Treated with Crizotinib

K.L. Davis, J.A. Kaye, E.T. Masters, S. Iyer

Current Oncology. 2018;25(1):40-49

Link1 Link2 Link3

Successful Crizotinib Rechallenge After Crizotinib-Induced Interstitial Lung Disease in Patients With Advanced Non–Small-Cell Lung Cancer

Nobuhiro Asai, Etsuro Yamaguchi, Akihito Kubo

Clinical Lung Cancer. 2014;15(3):e33-e35

Link1 Link2

Drug-induced reduction in estimated glomerular filtration rate in patients with ALK-positive non-small cell lung cancer treated with the ALK inhibitor crizotinib

Evelyn M. Brosnan, Andrew J. Weickhardt, Xian Lu, Delee A. Maxon, Anna E. Barón, Michel Chonchol, D. Ross Camidge

Cancer. 2013;120(5):664-674

Link1 Link2

FACTORS ASSOCIATED WITH CRIZOTINIB EFFICACY IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER HARBORING DIFFERENT ALK FUSION VARIANTS

Respirology. 2018;23:288-289

Link1 Link2

Post-crizotinib management of effective ceritinib therapy in a patient with ALK-positive non-small cell lung cancer

Brian Won, Isa Mambetsariev, Ravi Salgia

BMC Cancer. 2016;16(1):

Link1

Link2 Link3 Link4

This metadata service is kindly provided by CrossRef from May 29, 2014. Cancer Res Treat has participated in CrossRef Text and Data Mining service since October 29, 2014.